COMPASS Pathways plc (COMPASS Pathways Plc - American) aksje
CMPS
Pre-market$14.19+1.13 (+8.65%)
Pre-Market:$14.02-0.17 (-1.20%)
Laster graf...
COMPASS Pathways Plc - American
Market Cap
$1,914,930,688
Åpning13.35
Høy14.76
Lav13.09
Volum8.91M
P/EN/A
Markedsverdi1.91B
52-ukers høy14.76
52-ukers lav2.25
Gj.sn. volum3.99M
UtbytteN/A
Beta2.40
EPS-3.14
Om COMPASS Pathways plc (COMPASS Pathways Plc - American) aksje
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Selskapsinformasjon
Børs: NasdaqGS (NMS)
Sektor: Sundhed
Industri: Sundheds- og plejefaciliteter
Adresse:
33 Broadwick Street
W1F 0DQ London, United Kingdom
W1F 0DQ London, United Kingdom
Telefon: + 44 716 6766461
Nettside: https://compasspathways.com
Analytikernes aksjeanbefalinger
Denne oversikten gir et raskt innblikk i hvordan analytikere vurderer aksjens potensial basert på deres siste analyser og kursmål.
Anbefaling:1.33 - Stærk køb
Laveste kursmål
8.00
↓ 43.6%
Gjennomsnittlig kursmål
22.20
↑ 56.4%
Median kursmål
18.00
↑ 26.8%
Høyeste kursmål
70.00
↑ 393.3%